Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.



Drake, Thomas, Docherty, Annemarie, Harrison, Ewen ORCID: 0000-0002-5018-3066, Quint, Jennifer, Adamali, Huzaifa, Adamali, Huzaifa, Agnew, Sarah, Babu, Suresh, Barber, Christopher, Barratt, Shaney
et al (show 62 more authors) (2020) Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Rationale</h4> The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. <h4>Objectives</h4> To assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population. <h4>Methods</h4> An international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death. <h4>Measurements and Main Results</h4> Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and comorbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13−3.46). <h4>Conclusions</h4> Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.

Item Type: Article
Uncontrolled Keywords: ISARIC4C Investigators
Depositing User: Symplectic Admin
Date Deposited: 08 Jan 2021 15:24
Last Modified: 25 Mar 2021 15:53
DOI: 10.1101/2020.07.15.20152967
Open Access URL: https://doi.org/10.1101/2020.07.15.20152967
URI: https://livrepository.liverpool.ac.uk/id/eprint/3112071